Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Phase 2 Completed 214 enrolled PegBio Co., Ltd. Covance · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase 2, multicenter study to evaluate the efficacy and safety of twelve once weekly subcutaneous doses of PB-119 to patients with type 2 diabetes mellitus (T2DM) not well-controlled by metformin mono therapy.

Timeline

Start: 2018-06-13
Primary completion: 2019-07-23
Completion: 2019-07-23

Publications

Park EJ, Choi J, Lee KC, Na DH. Emerging PEGylated non-biologic drugs. Expert Opin Emerg Drugs. 2019 Jun;24(2):107-119. doi: 10.1080/14728214.2019.1604684. Epub 2019 Apr 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PB-119	Peptide	100 ug	Subcutaneous
Subject	PB-119	Peptide	150 ug	Subcutaneous
Subject	PB-119	Peptide	200 ug	Subcutaneous
Background	Metformin	Small molecule	—	Oral

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications